Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

Podda, Audino; Luca, E. Carapella-de; Titone, Lucina; Casadei, Anna Maria; Cascio, Antonio; Bartalini, M; Volpini, Gianfranco; Peppoloni, Samuele; Marsili, I.; Nencioni, L; Rappuoli, Rino

doi:10.1016/s0022-3476(05)81543-4

Cited by 27 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Podda et al, focused on childhood vaccination and showed how PTNA titers increased from 1.1 (pre-vaccination) to 269.1 (after three doses). Interestingly, the titer increased highly after the second dose, whereas after the first dose there was almost no increase in the titer, an observation that also was shared in other studies [ 8 , 47 ]. These neutralizing antibodies were still detectable after five years [ 48 ].…”

Section: The Role Of Neutralizing Antibodies To Pertussis Toxin (Ptnas)supporting

confidence: 82%

See 1 more Smart Citation

Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality

Barkoff

Knuutila

Mertsola

et al. 2021

Toxins

View full text Add to dashboard Cite

Pertussis toxin (PT) is considered the main virulence factor causing whooping cough or pertussis. The protein is widely studied and its composition was revealed and sequenced already during the 1980s. The human immune system creates a good response against PT when measured in quantity. However, the serum anti-PT antibodies wane rapidly, and only a small amount of these antibodies are found a few years after vaccination/infection. Therefore, multiple approaches to study the functionality (quality) of these antibodies, e.g., avidity, neutralizing capacity, and epitope specificity, have been investigated. In addition, the long-term B cell memory (Bmem) to PT is crucial for good protection throughout life. In this review, we summarize the findings from functional PT antibody and Bmem studies. These results are discussed in line with the quantity of serum anti-PT antibodies. PT neutralizing antibodies and anti-PT antibodies with proper avidity are crucial for good protection against the disease, and certain epitopes have been identified to have multiple functions in the protection. Although PT-specific Bmem responses are detectable at least five years after vaccination, long-term surveillance is lacking. Variation of the natural boosting of circulating Bordetella pertussis in communities is an important confounding factor in these memory studies.

show abstract

Section: The Role Of Neutralizing Antibodies To Pertussis Toxin (Ptnas)supporting

confidence: 82%

“…A new genetically inactivated recombinant PT vaccine was developed, in which the enzymatic activity was inactivated through precise genetic modifications. Later, the recombinant PT vaccine was combined with FHA and PRN and was shown to be immunogenic and safe in infants, and induced early and long-lasting protection [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality

Barkoff

Knuutila

Mertsola

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…The safety and superior immunogenicity of a 9K/129G genetically-detoxified PT (rPT) was demonstrated long ago [21,22]: rPT has similar immunological and functional properties as native PT and thus higher immunogenicity than cdPT at similar doses [19, , 23-25]. BioNet-Asia (BNA) developed a new rPT-expressing B. pertussis strain [26].…”

Section: Introductionmentioning

confidence: 99%

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Blanchard-Rohner

Chatzis

Chinwangso³

et al. 2018

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The genetically detoxified PT had successfully shown its safety and immunogenicity in clinical trials, both in adult volunteers and in infants and children, either as a monovalent mutant PT alone [62,63], or in association with FHA and pertactin [64,65], and also with FHA and pertactin in association with diphtheria and tetanus toxoids (DTaP) [66,67]. These trials showed that the different acellular vaccine formulations containing the non-toxic PT mutant were extremely safe, and much safer than the wholecell pertussis vaccines.…”

Section: Genetically Detoxified Vaccinesmentioning

confidence: 99%

Novel vaccination strategies

Lattanzi

Rappuoli

2005

The Grand Challenge for the Future

Self Cite

View full text Add to dashboard Cite

show abstract

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

Cited by 27 publications

References 6 publications

Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality

Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Novel vaccination strategies

Contact Info

Product

Resources

About